Cart

0

Stocks

“Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks”

“…RegenXBio (RGNX)

The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies….  Choi rates RGNX a Buy along with a $38 price target. This figure indicates room for a one-year upside of 165%. (To watch Choi’s track record, click here)…

Viridian Therapeutics (VRDN)

The second stock on today’s list is Viridian Therapeutics, a biotech firm whose work focuses on the development of novel treatments for autoimmune diseases… Along with that Buy rating, Law gives Viridian shares a $23 price target, suggesting a 38% upside over a one-year horizon. (To watch Law’s track record, click here)…”

https://finance.yahoo.com/news/goldman-sachs-predicts-165-surge-130927486.html


 

Leave a Reply